12 results about "Immunoglobulin G" patented technology

This invention provides a bovine colostrum IgG nutritional supplement gummies and their preparation method, belonging to the field of functional food technology. The bovine colostrum IgG nutritional supplement gummies of this invention, through precise formulation of specific components, effectively improve the dispersion uniformity of whole-fat bovine colostrum freeze-dried powder in the gummy base, significantly retaining the activity of immunoglobulin G, giving the product a stable texture and good taste; further, combined with a special process adapted to the formula, high yield and high raw material utilization are achieved in industrial production. This product combines immune nutritional supplementation with convenient consumption, making it suitable for people of all ages and possessing good market application prospects.

This invention relates to the fields of biomedical technology and biological model construction technology, and discloses an ANCA-associated vasculitis glomerular endothelial cell injury model, its construction method and application, and the application of BACH1 inhibitors. The method includes: (1) activating neutrophils sequentially with tumor necrosis factor α and immunoglobulin G to obtain a culture medium containing activated neutrophils; wherein the immunoglobulin G is immunoglobulin G isolated and purified from the plasma of patients with ANCA-associated vasculitis; (2) co-culturing the culture medium containing activated neutrophils with human glomerular endothelial cells to obtain the cell injury model. The cell injury model provided by this invention can verify the role of neutrophil adhesion characteristics in endothelial cell injury, and at the same time, the cell injury model can better simulate the immune microenvironment of ANCA-associated vasculitis glomerular endothelial cells in vivo.

The application relates to the field of biological medicine, and particularly discloses application of saliva TP17, TP47 and TP15 specific antibodies in preparation of an auxiliary diagnostic product for neurosyphilis. Based on specific antibody immunoglobulin G (IgG) of Treponema pallidum in saliva, combined detection of saliva TP17 / IgG, TP47 / IgG and TP15 / IgG outputs a risk value of neurosyphilis of a subject, or a four combined Logistic regression discriminant model is constructed by combining serum TRUST titers, and the subject is stratified into a low-risk or high-risk group based on a preset judgment threshold, so that the comprehensive recognition capability for neurosyphilis is improved. The saliva is used as a detection sample, and the application has the advantages of non-invasiveness, convenience, easy popularization, repeatable collection and the like, and can be used for early screening, auxiliary diagnosis and clinical path management of neurosyphilis.

FIELD: clinical gastroenterology.SUBSTANCE: intended to predict the risk of relapse of autoimmune hepatitis after discontinuation of immunosuppressive therapy. The patient undergoes a clinical and biochemical examination and the relapse risk probability index is determined using the formula: PI RR = –0.394×(IGA≥ 9) + 1.252×(AT) + 0.915×(a-SLA / LP) + 0.555×(a-LKM1) – 0.692×(IgG norm) + 0.316×(obesity), where PI RR is the prognostic index of recurrence risk; HAI is the histological activity index of more than 9 according to Knodell (binary indicator: HAI ≥ 9 corresponds to the multiplier “1”; HAI < 9 corresponds to the multiplier “0”); AB – the presence of autoantibodies (binary indicator: detection of at least 1 corresponds to the multiplier “1”; absence of autoantibodies corresponds to the multiplier “0”); a-SLA / LP – antibodies to soluble liver / kidney antigen (binary indicator: presence – corresponds to the multiplier “1”; absence – corresponds to the multiplier “0”); a-LKM1 – antibodies to liver and pancreas microsomes (binary indicator: presence corresponds to the multiplier “1”; absence corresponds to the multiplier “0”); IgG – immunoglobulin G (binary indicator: normal Ig G level corresponds to the multiplier “1”; elevated IgG level corresponds to the multiplier “0”); obesity (BMI ≥ 30) – (binary indicator: presence of BMI ≥ 30 corresponds to a multiplier of “1”; BMI < 30 corresponds to the multiplier “0”). With the value of PI RR < 0.93 – low probability of relapse, PI RR > 0.93 – high probability of relapse.EFFECT: increased accuracy in predicting the risk of recurrence of autoimmune hepatitis after discontinuation of immunosuppressive therapy.1 cl, 2 ex

The present invention relates to a method and system for extracting proteins, in particular recombinant and / or plasma-derived proteins, including immunoglobulins (Ig), such as immunoglobulin G (IgG), from precipitate.

The present application relates to the field of food technology, and specifically discloses a composition for reducing gastroesophageal reflux in individuals, a preparation method and application thereof. The composition for reducing gastroesophageal reflux in individuals comprises lactadherin, medium-long chain triglyceride, human milk oligosaccharide and immunoglobulin G. The present application constructs a multi-target synergistic intervention mechanism combining physical protection, secretion regulation and tissue repair through the compounding of four core components, which can comprehensively block the occurrence and development of gastroesophageal reflux. Lactadherin constructs a physical barrier to reduce the risk of reflux dynamics from the source; MLCT precisely regulates gastric acid secretion, reducing chemical stimulation; HMO compound IgG strengthens the mucosal immune barrier and promotes damage repair. The above composition is applied to products for reducing gastroesophageal reflux in individuals, and multi-target synergistic effect is achieved, realizing the whole-chain closed-loop intervention from prevention, relief to repair, and significantly improving the clinical improvement effect.

Provided herein are cyclic peptides capable of binding to and inhibiting neonatal fragment crystallizable receptor (FcRn) proteins, and methods of using the same for the treatment and / or prevention of various diseases, including conditions associated with FcRn activity and / or immunoglobulin G (IgG) autoantibody levels in a subject.

This invention belongs to the field of biological agents and biomedicine, specifically relating to the application of *Lactobacillus reuteri* PFL-2501 and its agents in the treatment of *Helicobacter pylori*. This invention discovers that *Lactobacillus reuteri* PFL-2501 and its agents can alleviate gastritis and systemic inflammatory responses caused by *Helicobacter pylori* infection, effectively improving gastritis symptoms and reducing the severity of infection. The results of the embodiments show that *Lactobacillus reuteri* PFL-2501 has comprehensive functions, can inhibit *Helicobacter pylori*, regulate immune balance, has a good inhibitory effect on urease activity, and can reduce the levels of pro-inflammatory factors TNF-α, IL-1β, and IL-6 in serum, as well as reduce the level of immunoglobulin G, laying a research foundation for the subsequent development of anti-*Helicobacter pylori* products.

Provided herein are antibodies, recombinant proteins, and methods of use thereof including, for example, immunoglobulin G (IgG) antibodies and recombinant proteins including a Fab region and an Fc region connected through a hinge region, where the hinge region is resistant to cleavage by a protease. Also, provided herein, inter alia, are immunoglobulin G (IgG) antibodies and recombinant proteins including a Fab region and an Fc region connected through a hinge region, and where the Fc region has higher affinity for a ligand compared to a wildtype Fc.

Provided herein are cyclic peptides capable of binding to and inhibiting neonatal fragment crystallizable receptor (FcRn) proteins, and methods of using the same for the treatment and / or prevention of various diseases, including conditions associated with FcRn activity and / or immunoglobulin G (IgG) autoantibody levels in a subject.

The application provides use of L-xylulose as a diagnostic marker for children with Kawasaki disease of immunoglobulin G non-responsiveness, and application of L-xylulose as a diagnostic marker in preparation of a Kawasaki disease diagnosis product, the diagnostic marker being a marker in a sample of children with Kawasaki disease, and the Kawasaki disease diagnosis product including a product for predicting and / or evaluating treatment effect of Kawasaki disease. The application first proposes a diagnostic marker of children with Kawasaki disease of immunoglobulin G non-responsiveness of L-xylulose, and uses the diagnostic marker for predicting and / or evaluating treatment effect of Kawasaki disease, and has good stability and repeatability.

This invention discloses a method for isolating and purifying immunoglobulin G (IgG) from bovine colostrum powder, belonging to the field of protein isolation and purification technology. The method includes the step of eluting the immunoglobulin using an 80-120 mM NaCl-8-12 mM PBS solution with a pH of 5.4-6.4. This invention yields immunoglobulin G with a purity greater than 80%, which is beneficial for further research on its functional activity. This helps to understand the true metabolic pathway of IgG in vivo, clarify its immune efficacy mechanism, and provide a theoretical basis and guidance for the application and efficacy enhancement of IgG in infant formula, children's milk powder, and special dairy products.